Evaluation of the sensitivity pattern of ceftazidime-avibactam against multidrug-resistant gram-negative Isolates of Enterobacterales
DOI:
https://doi.org/10.55629/pakjpathol.v37i3.1011Abstract
Objectives: Surveillance of antimicrobial susceptibility patterns is essential for guiding effective therapy. This study aimed to evaluate the in vitro activity of ceftazidime-avibactam against Enterobacterales stratified by resistance phenotype.
Material and Methods: This retrospective, laboratory-based surveillance study was conducted from 1st February to 30th November 2023 at the National Institute of Cardiovascular Diseases, a tertiary care cardiac centre in Karachi, Pakistan. We analysed 236 non-duplicate Enterobacterales isolates obtained from 98 blood and 138 respiratory specimens. Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute guidelines. Associations between resistance phenotype and ceftazidime-avibactam susceptibility were assessed using the Chi-square test, Cramér’s V, linear-by-linear association, and odds ratios with 95% confidence intervals.
Results: Overall, 179/236 (75.8%; 95% CI: 70.0–80.9) isolates were susceptible, and 57/236 (24.2%; 95% CI: 19.1–30.0) were resistant to ceftazidime-avibactam. Among blood isolates, susceptibility declined from 95.0% in non-Multidrug resistant organisms (non-MDRO) to 30.3% in carbapenem-resistant Enterobacterales (CRE) isolates (χ² = 32.08, p < 0.001). Respiratory isolates showed a similar decrease from 97.1% to 34.5% (χ² = 55.83, p < 0.001). Significant linear trends of decreasing susceptibility across resistance phenotypes were observed in both specimen groups. CRE isolates had significantly higher odds of resistance than ESBL producers.
Conclusion: Ceftazidime-avibactam demonstrated high activity against non-MDRO and ESBL-producing Enterobacterales but reduced efficacy against CRE isolates, with susceptibility declining progressively across resistance phenotypes in both blood and respiratory specimens.
Keywords: Beta-lactamase inhibitors, Carbapenem-resistant enterobacteriaceae, Ceftazidime, Drug resistance, Microbial, Sensitivity test
References
Lim TP, Ho JY, Teo JQ, Sim JH, Tan SH, Tan TT, et al. In vitro susceptibility to ceftazidime-avibactam and comparator antimicrobial agents of carbapenem-resistant Enterobacterales isolates. Microorganisms. 2023; 11(9): 2158. DOI: https://doi.org/10.3390/microorganisms11092158
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, ampc-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018; 31(2). DOI: https://doi.org/10.1128/cmr.00079-17
GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021: A systematic analysis with forecasts to 2050. Lancet. 2024; 404(10459): 1199-226. DOI: https://doi.org/10.1016/s0140-6736(24)01867-1
Umair M, Walsh TR, Mohsin M. A systematic review and meta-analysis of carbapenem resistance and its possible treatment options with focus on clinical Enterobacteriaceae: Thirty years of development in Pakistan. Heliyon. 2024; 10(7): e28052. DOI: https://doi.org/10.1016/j.heliyon.2024.e28052
Jayathilaka N, Shehana S, Nakkawita D, Senaratne T. Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis. Systematic Rev. 2025; 14(1): 123.
DOI: https://doi.org/10.1186/s13643-025-02776-5
Vougiouklakis G, Tsioutis C, Vasileiadi N, Alexakis K, Spernovasilis N, Agouridis AP. Ceftazidime/ Avibactam monotherapy versus other antibiotics: Where do we stand? Pathogens. 2025; 14(11): 1119. DOI: https://doi.org/10.3390/pathogens14111119
Ali EM, Bakri HA, Banji OJF, Khardali A, Alfarhan M, Thaibah HA, et al. Assessment of clinical effectiveness and safety of ceftazidime-avibactam in ‐treating multi-drug-resistant infections – A retrospective analysis at a tertiary care hospital in Saudi Arabia. J Infect Public Health. 2025; 18(9): 102841. DOI: https://doi.org/10.1016/j.jiph.2025.102841
Wise MG, Karlowsky JA, Hackel MA, Harti MA, Ntshole BME, Njagua EN, et al. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021. J Global Antimicrob Resist. 2023; 35: 93-100. DOI: https://doi.org/10.1016/j.jgar.2023.08.022
Gales AC, Stone G, Sahm DF, Wise MG, Utt E. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017–2019. J Antimicrob Chemotherapy. 2023; 78(7): 1606-15. DOI: https://doi.org/10.1093/jac/dkad127
Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, et al. Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res. 2023; 266: 127249.
DOI: https://doi.org/10.1016/j.micres.2022.127249
Maraolo AE, Gallicchio A, Fotticchia V, Catania MR, Scotto R, Gentile I. Clinical outcomes and predictors of mortality in patients with difficult-to-treat resistant pseudomonas aeruginosa infections: A retrospective cohort study. Antibiotics. 2026; 15(1): 33. DOI: https://doi.org/10.3390/antibiotics15010033
Gras-Martín L, Plaza-Diaz A, Zarate-Tamames B, Vera-Artazcoz P, Torres OH, Bastida C, et al. Risk factors associated with antibiotic exposure variability in critically ill patients: A systematic review. Antibiotics. 2024; 13(9): 801.
DOI: https://doi.org/10.3390/antibiotics13090801
Mehdi N, Majeed N, Ali F, Aroob I. High ceftazidime-avibactam resistance rate in carbapenem-resistant gram-negative organisms in Pakistan's pediatric population. Pak J Med Sci. 2025; 41(3): 788-91. DOI: https://doi.org/10.12669/pjms.41.3.9978
Mehmood MS, Ambreen F, Hareem G, Fouzia Zeeshan K, Hira Z, Saima N. Susceptibility pattern of Ceftazidime-Avibactam against multi drug resistant gram-negative rods. Liaquat Med Res J. 2024; 6(3). 132-7. DOI: https://doi.org/10.38106/LMRJ.2024.6.3-03
Chaudhry M, Jabeen K, Tufail Z, Mustafa S, Zahra SFT, Mahmood S. Frequency of ceftazidime-avibactam resistance in pseudomonas aeruginosa: Experience at a tertiary care hospital. TPMJ. 2024; 31(11): 1608-12. DOI: https://doi.org/10.29309/TPMJ/2024.31.11.8312
Ahsan M, Adnan F, Khan MA, Khursheed N. Evaluation of in-vitro activity of ceftazidime-avibactam against carbapenem-resistant gram-negative bacteria: A cross-sectional study from Pakistan. J Exploratory Res Pharmacol. 2025; 10(1): 3-8. DOI: https://doi.org/10.14218/JERP.2025.00001
Noreen N, Aslam A, Abbas M, Ghulam Mustafa A, Jamshed S, Gajdács M, et al. Multicentric surveillance of antimicrobial resistance to generate data-driven regional antibiograms: A laboratory-based cross-sectional study in Pakistan. Antibiotics. 2025; 14(11): 1154. DOI: https://doi.org/10.3390/antibiotics14111154
Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013; 6(1): 14-7. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4017493/pdf/GHFBB-6-014.pdf
Dobhal S, Sen M, Yadav H, Agarwal J, Das A, Chandra A, et al. Role of ceftazidime-avibactam in urinary tract infections caused by carbapenem-resistant Enterobacterales. Cureus. 2024; 16(12): e75221. Available from: https://pmc.ncbi.nlm.nih. gov/articles/PMC4017493/pdf/GHFBB-6-014.pdf
Schuetz AN, Ferrell A, Hindler JA, Humphries R, Bobenchik AM. Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions. J Clin Microbiol. 2025; 63(9): e01623-23. DOI: https://doi.org/10.1128/jcm.01623-23
El Kettani A, Zoukal S, Zerouali K, Hassoune S, Soussi-Abdallaoui M. In vitro activity of ceftazidime – avibactam against Enterobacteriaceae and P. aeruginosa Isolated at the Ibn Rochd University Hospital of Casablanca. Clin Lab. 2023; 69(10). DOI: https://doi.org/10.7754/Clin.Lab.2023.230401
Wang Y, Sholeh M, Yang L, Shakourzadeh MZ, Beig M, Azizian K. Global trends of ceftazidime–avibactam resistance in gram-negative bacteria: systematic review and meta-analysis. Antimicrob Resist Infect Control. 2025; 14(1): 10. DOI: https://doi.org/10.1186/s13756-025-01518-5
Zalas-Więcek P, Prażyńska M, Pojnar Ł, Pałka A, Żabicka D, Orczykowska-Kotyna M, et al. Ceftazidime/avibactam and other commonly used antibiotics activity against Enterobacterales and pseudomonas aeruginosa isolated in Poland in 2015–2019. Infect Drug Resist. 2022: 1289-304. DOI: https://doi.org/10.2147/IDR.S344165
Ain NU, Hannan A, Imran N, Ali A, Rasheed F, Sultan S, et al. New Delhi metallo-β-lactamases among extensively drug-resistant clinical isolates from Lahore, Pakistan. Future Microbiol. 2024; 19(11): 971-81. DOI: https://doi.org/10.1080/17460913.2024.2343600
Noori M, Karimi A, Fallah F, Hashemi A, Alimehr S, Goudarzi H, et al. High prevalence of metallo-beta-lactamase producing Acinetobacter baumannii isolated from two hospitals of Tehran, Iran. 2014. DOI: https://doi.org/10.5812/pedinfect.15439
Wei W-J, Yang H-F, Ye Y, Li J-B, Chen X. New Delhi Metallo-β-Lactamase-Mediated Carbapenem Resistance: Origin, Diagnosis, Treatment and Public Health Concern. Chin Med J. 2015; 128(14): 1969-76. DOI: https://doi.org/10.4103/0366-6999.160566
Shabi Y, Hadi G, Algarni A, Al Bshabshe A, Alazraqi T, Abdullah S, et al. Carbapenem resistance and multidrug resistance in Morganellaceae: A 12-year retrospective cross-sectional study from southern Saudi Arabia. Ann Clin Microbiol Antimicrob. 2025; 25(1): 10. DOI: https://doi.org/10.1186/s12941-025-00844-1
Chen S, Fan J, Xiao T, Ren J, Zhu H, Kong H, et al. Incidence and risk factors of active carbapenem – resistant Enterobacteriaceae surveillance in hematology patients: A propensity score matching study. Front Microbiol. 2025; 16. DOI: https://doi.org/10.3389/fmicb.2025.1561587
Tunyong W, Arsheewa W, Santajit S, Kong-Ngoen T, Pumirat P, Sookrung N, et al. Antibiotic Resistance Genes Among Carbapenem-resistant Enterobacterales (CRE) Isolates of Prapokklao Hospital, Chanthaburi Province, Thailand. Infect Drug Resist. 2021; 14: 3485-94. DOI: https://doi.org/10.2147/idr.S328521
Bandac CA, Ristescu C, Onofrei P, Miftode I-L, Radu R, Boiculese VL, et al. Assessment of factors contributing to multidrug resistance in urinary tract infections: Focus on carbapenem resistance. Antibiotics. 2025; 14(9): 918. DOI: https://doi.org/10.3390/antibiotics14090918
Boattini M, Bianco G, Bastos P, Comini S, Corcione S, Almeida A, et al. Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022). Eur J Clin Microbiol Infect Dis. 2024; 43(1): 155-66. DOI: https://doi.org/10.1007/s10096-023-04712-8
Colaneri M, Montrucchio G, Scaglione G, Monti G, Tricella G, Genovese C, et al. Incidence, microbiology, and mortality of ventilation-associated pneumonia in a large Italian cohort of critically ill patients: results from the PROSAFE project. Clin Microbiol Infect. 2025; 31(9):1491-9. DOI: https://doi.org/10.1016/j.cmi.2025.05.026
Piérard D, Stone GG. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). BMC Infect Dis. 2021; 21(1): 600. DOI: https://doi.org/10.1186/s12879-021-06153-0
Golli A-L, Zlatian OM, Popa S-G, Turcu FL, Balasoiu AT. Trends in the Antimicrobial Resistance Pattern of Bacterial Gram-Negative Pathogens in Elderly Patients Admitted to the Intensive Care Unit. Microorganisms. 2025; 13(10): 2330. DOI:https://doi.org/10.3390/microorganisms13102330
Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024: ciae403. DOI: https://doi.org/10.1093/cid/ciae403
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Faiza Rezwan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
